A phase IV post-marketing study of OFEV for the treatment of idiopathic pulmonary fibrosis (IPF)
Phase of Trial: Phase IV
Latest Information Update: 25 Nov 2015
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- 25 Nov 2015 New trial record
- 13 Nov 2015 According to a Boehringer Ingelheim media release, results from this study will be presented at the Pulmonary Fibrosis Foundation's PFF Summit 2015.
- 13 Nov 2015 Results published in a Boehringer Ingelheim media release.